Prostate Cancer Program
Medical Oncology Branch
Radiation Oncology Branch
Urologic Oncology Branch
Mission
The Prostate Cancer Program’s three major goals are clinical research, clinical care, and clinical training to improve management of patients with prostate cancer. Specifically, the prostate cancer team strives to:
- Design and test new therapeutic research strategies for the treatment of patients with prostate cancer
- Provide excellent multi-disciplinary clinical care to prostate cancer patients
- Educate its trainees with a comprehensive clinical experience in the management of all types of prostate cancer in a multi-disciplinary setting
Overview
The Prostate Cancer Program's multi-disciplinary clinic meets weekly in the Clinical Center and incorporates the expertise from urologic oncology, medical oncology, diagnostic radiology, pathology, and radiation oncology to discuss and provide an individualized treatment strategy for each patient. Clinical research trials are conducted by principal investigators, physicians, nurses, and staff of the above-mentioned departments at the National Cancer Institute (NCI), National Institutes of Health (NIH). The Prostate Cancer Program develops clinical trials to investigate experimental and current treatment options for men with prostate cancer.
The program’s trials are currently enrolling men with:
- Low-risk prostate cancer
- High-risk prostate cancer
- Recurrent/non-metastatic prostate cancer
- Prostate cancer and rising PSA without metastasis on hormonal therapy Prostate cancer and rising PSA without metastasis on hormonal therapy
- Metastatic prostate cancer
Research Team
William L. Dahut, M.D.
Principal Investigator
Clinical Director of CCR, NCI
Chief, GU/GYN Clinical Research Section
Medical Oncology Branch and Affiliates, CCR, NCI
Dr. William L. Dahut received his M.D. from Georgetown University in Washington, D.C. He completed clinical training in internal medicine at the National Naval Medical Center in Bethesda, Md., followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of NCI. Dr. Dahut worked as an attending physician in the NCI-Navy Medical Oncology Branch until 1995. He then joined the faculty of the Lombardi Cancer Center at Georgetown University before returning to the former NCI Medicine Branch in 1998 as head of the prostate cancer clinic. Dr. Dahut is the clinical director of NCI and chief of the GU/GYN Clinical Research Section in the Medical Oncology Branch. Dr. Dahut’s primary research interest has been in the development of novel therapeutic strategies for the treatment of adenocarcinoma of the prostate.
James L. Gulley, M.D., Ph.D., F.A.C.P.
Head, Clinical Trials Group
Deputy Laboratory Chief,
Laboratory of Tumor Immunology and Biology, Medical Oncology Branch and Affiliates, CCR, NCI
Dr. James L. Gulley is a board certified medical oncologist. He is deputy chief of the Laboratory of Tumor Immunology and Biology (LTIB) at the National Cancer Institute (NCI) and director of the LTIB's Clinical Trials Group. He is a senior investigator within the Medical Oncology Branch. He received his medical training at Loma Linda University in its medical scientist training program, where he obtained a Ph.D. with his work in tumor immunology as well as an M.D. He went to Emory University for a residency in internal medicine and then to the National Cancer Institute for a fellowship in Medical Oncology. Following his fellowship, he was retained as senior staff at NCI.
Since 1999, Dr. Gulley has been involved in designing and running numerous clinical trials in prostate cancer at NCI. He has been an investigator on approximately 50 trials and has been the PI on 20. Most of the studies he has run use therapeutic vaccines for solid tumors. He has received multiple awards including, a shared NIH Group Merit Award “for major contributions to the field of cancer immunotherapy,” another NIH Group Merit Award “for making enormous strides in the treatment of several different stages of prostate cancer,” and the Presidential Early Career Award for Science and Engineering “for randomized, controlled studies using novel, recombinant vaccines to reduce the progression of prostate and other cancers and increase survival.” He has authored more than 150 original articles, reviews, and book chapters on immunotherapy and cancer treatments and has delivered numerous invited presentations at national and international meetings.
Ravi A. Madan, M.D.
Assistant Clinical Investigator
Laboratory of Tumor Immunology and
Biology, Medical Oncology Branch and Affiliates, CCR, NCI
Dr. Ravi A. Madan is an assistant clinical investigator at the National Cancer Institute (NCI), conducting clinical research in therapeutic cancer vaccines and genitourinary malignancies. Dr. Madan received his M.D., from the UMDNJ–New Jersey Medical School in 2001 and completed his internal medicine residency at UMDNJ–University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/ hematology fellow in 2005. He currently holds a joint appointment in the Medical Oncology Branch and the Laboratory of Tumor Immunology and Biology. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
Peter A. Pinto, M.D.
Principal Investigator
Urologic Oncology Branch, CCR, NCI
Dr. Peter A. Pinto is a Senior Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.
Aradhana Kaushal, M.D.
Staff Clinician
Radiation Oncology Branch, CCR, NCI
Dr. Aradhana Kaushal graduated with a B.A./M.D., magna cum laude, from Boston University in 2002. She completed a year at the National Cancer Institute conducting research under the direction of Dr. Norman Coleman and Dr. David Gius, studying a possible mechanism for resistance of tumor cells to oxidative stress, which involves control of gene expression through transcription factor activation, methylation, and protein chaperone compartmentalization. She completed her internship in internal medicine in 2003 at Lenox Hill Hospital, a teaching hospital of New York University in Manhattan. Dr. Kaushal completed a residency in radiation oncology in 2007 at the Thomas Jefferson University Hospital in Philadelphia, Pa., and served as chief resident from 2006–2007. Her clinical focus is prostate and pediatric malignancies. Dr. Kaushal is board certified by the American Board of Radiology.
Back to Top
